AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9643623
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR 180 mg and trandolapril 0.5 mg
Trial: 9643623
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR 180 mg and trandolapril 1.0 mg
Trial: 9643623
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR (120, 180 mg) and trandolapril (0.5, 1.0, 2.0 mg)
Trial: 3062528
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% levobunolol before unilateral Nd:YAG laser posterior capsulotomy
Trial: 3062528
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% levobunolol after unilateral ECCE
Trial: 21577010
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg opipramol
Trial: 11273498
Drug: Interferon-alpha (IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN) therapy, 5 million units (MU) subcutaneously thrice a week for 12 weeks
Trial: 11273498
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (Control)
Trial: 9109139
Drug: Amoxicillin once
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin once daily (qd)
Trial: 9109139
Drug: Amoxicillin twice
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin twice daily (bid)
Trial: 9109139
Drug: Amoxicillin (qd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (qd or bid)
Trial: 9109139
Drug: Amoxicillin (qd)
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin (qd) vs. Amoxicillin (bid)
Trial: 9109139
Drug: Amoxicillin (qd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (qd or bid) vs. Placebo
Trial: 1394811
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Adriamycin (ADM) + 200 mg cytosine arabinoside (CA) in 30 ml physiological saline (group A)
Trial: 1394811
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg peplomycin (PEP) + 200 mg CA in 30 ml physiological saline (group B)
Trial: 1394811
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg neocarzinostatin (NCS) + 200 mg CA in 30 ml physiological saline (group C)
Trial: 1394811
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ADM + 200 mg CA in 30 ml physiological saline + 300 mg/day UFT (group E)
Trial: 1394811
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ADM + 200 mg CA in 30 ml physiological saline + 200 mg 5‐fluorouracil (5‐FU)/day (group F)
Trial: 1394811
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ADM + 200 mg CA in 30 ml physiological saline + 30 mg ubenimex/day (group G)
Trial: 1394811
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral drug (group H)
Trial: 3840612
Drug: Bromopride (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromopride (20 mg) administered via i.v. injection half an hour before chemotherapy and at 3 1/2 and 7 1/2 hours following chemotherapy.
Trial: 3840612
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via i.v. injection half an hour before chemotherapy and at 3 1/2 and 7 1/2 hours following chemotherapy.
Trial: 3840612
Drug: Bromopride (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromopride (20 mg)
Trial: 22368996
Drug: Kinesiology treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesiology treatment for a period of 6 months
Trial: 19373423
Drug: Control (placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo, H2 receptor antagonist, or somatostatin)
Trial: 17499091
Drug: One-step self-etching
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-step self-etching adhesives (G-Bond, iBond, Clearfil S(3))
Trial: 11590678
Drug: Beta-radiation therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-radiation therapy ((188)Re-MAG(3))
Trial: 9833601
Drug: Acipimox (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (500 or 750 mg daily for 12 weeks)
Trial: 9695160
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant human growth hormone over eight weeks
Trial: 1677821
Drug: Pancuronium (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (0.10 mg/kg)
Trial: 1677821
Drug: Vecuronium (0.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.09 mg/kg)
Trial: 6307135
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g twice daily
Trial: 6307135
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g once daily
Trial: 6307135
Drug: Ceftriaxone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone therapy continued after discharge
Trial: 6307135
Drug: Ceftriaxone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone therapy
Trial: 30128705
Drug: Talcom 75
RxNorm normalized name: Talco
DrugBank: Talc (DB09511)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Talcom 75 mg od + aspirin 100 mg od
Trial: 30128705
Drug: Plavix 75
RxNorm normalized name: Plavix 75mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plavix 75 mg od + aspirin 100 mg od
Trial: 21108204
Drug: Propofol (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (bolus 1 mg/kg, followed by increments containing 20% of the initial dose)
Trial: 21108204
Drug: Etomidate (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (bolus 0.15 mg/kg, followed by increments containing 20% of the initial dose) and 1 mg/kg of fentanyl i.v. (single dose)
Trial: 18751504
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of terbinafine (250 mg)
Trial: 18751504
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of terbinafine (250 mg)
Trial: 15998354
Drug: ACTH(1-24) 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH(1-24) 1.0 mg intramuscularly daily for four days
Trial: 15998354
Drug: ACTH(1-24) 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH(1-24) 0.5 mg intramuscularly daily for four days
Trial: 15998354
Drug: ACTH(1-24) 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH(1-24) 0.1 mg intramuscularly daily for four days
Trial: 15998354
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% 1 ml intramuscularly daily for four days (Control)
Trial: 15998354
Drug: ACTH(1-24) 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH(1-24) 1.0 mg intramuscularly five times at an interval of four days
Trial: 8043704
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate treatment for 4 weeks
Trial: 3414571
Drug: Diet‐plus‐behavior (DB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet‐plus‐behavior (DB) therapy
Trial: 3414571
Drug: Exercise‐plus‐diet‐plus‐behavior (EDB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise‐plus‐diet‐plus‐behavior (EDB) therapy
Trial: 4877600
Drug: I.C.I. 50172
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.C.I. 50172 (20 mg)
Trial: 4877600
Drug: I.C.I. 50172
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.C.I. 50172 (4 mg)
Trial: 29119418
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) at doses of 3, 6, and 9 J/diode (135, 270, and 405 J/thigh) applied bilaterally to the quadriceps muscle before time-to-exhaustion tests.
Trial: 29119418
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment applied bilaterally to the quadriceps muscle before time-to-exhaustion tests.
Trial: 28237959
Drug: Benidipine 4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine 4-8 mg/day and fosinopril 20 mg/day
Trial: 28237959
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 12.5-25 mg/day and fosinopril 20 mg/day
Trial: 25337748
Drug: 4-month gatifloxacin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-month gatifloxacin-containing regimen (400 mg per day)
Trial: 12543744
Drug: 5% povidone-iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% povidone-iodine (PI) solution
Trial: 12543744
Drug: 1% povidone-iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% povidone-iodine (PI) solution
Trial: 1448587
Drug: Nebuhaler treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebuhaler treatment (1 mg of terbutaline and 80 micrograms of ipratropium bromide four times daily)
Trial: 1448587
Drug: Salbutamol nebulizer
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol nebulizer solution (5 mg)
Trial: 1448587
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nebulizer (0.5 mg)
Trial: 1448587
Drug: Mixed nebulizer
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed nebulizer treatment (salbutamol and ipratropium bromide)
Trial: 1448587
Drug: Home nebulizer
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home nebulizer treatment (chosen by patients)
Trial: 1448587
Drug: Usual inhaled
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual inhaled treatment (2 weeks prior to intervention)
Trial: 30074540
Drug: RV5 vaccine
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV5 vaccine first dose at <6 weeks
Trial: 30074540
Drug: RV1 vaccine
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV1 vaccine with a 4-week interval between doses
Trial: 30074540
Drug: RV5 vaccine
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV5 vaccine first dose at 3-4 weeks
Trial: 30074540
Drug: RV5 vaccine
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV5 vaccine first dose at 5-7 weeks
Trial: 30074540
Drug: RV5 vaccine
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV5 vaccine first dose at 8 weeks
Trial: 24669015
Drug: TR-FEC (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TR-FEC (paclitaxel 80 mg/m(2) i.v. and everolimus 30 mg PO weekly for 12 weeks, followed by FEC)
Trial: 24669015
Drug: T-FEC (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-FEC (paclitaxel 80 mg/m(2) i.v. weekly for 12 weeks, followed by FEC)
Trial: 18005366
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1 L clear liquids)
Trial: 18005366
Drug: Purgative group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purgative group (1 L PEG)
Trial: 9930904
Drug: Atropine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (2.0 mg intravenously)
Trial: 21131864
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of whey protein (PRO)
Trial: 21131864
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of whey protein plus 50 g of maltodextrin (PRO+CARB)
Trial: 21131864
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of CHO with 25 g of protein (PRO+CARB)
Trial: 19438818
Drug: Intermittent terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent terbinafine (TOT) 250 mg/day for 4 weeks followed by 4 weeks off, then 4 weeks of 250 mg/day
Trial: 19438818
Drug: Continuous terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous terbinafine (CTERB) 250 mg/day for 12 weeks
Trial: 19438818
Drug: Itraconazole (III)
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole (III) pulse of 200 mg twice daily for 7 days on, 21 days off, three pulses
Trial: 16484854
Drug: Cytostatic antineoplastic
RxNorm normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytostatic antineoplastic agents
Trial: 15051778
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV iron (iron dextran total dose infusion)
Trial: 15051778
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (325 mg twice daily)
Trial: 9152680
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 209 micromol of Vitamin A
Trial: 7957533
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg orlistat
Trial: 7957533
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg orlistat
Trial: 7957533
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg orlistat
Trial: 7957533
Drug: 360 mg
RxNorm normalized name: aspirin 360 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg orlistat
Trial: 31990087
Drug: TAK‐954 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK‐954 (0.5 mg intravenous over 1 hour)
Trial: 31990087
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg intravenous 4 times/d)
Trial: 29164826
Drug: Buffered 50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered 50% glycolic acid (pH 3.0) + 0.5% salicylic acid solution
Trial: 22092688
Drug: Active patch
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active patch (pulsed electromagnetic energy)
Trial: 18503714
Drug: Ibuprofen (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (7 mg/kg body weight, every eight hours)
Trial: 8712823
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 2 courses of chemotherapy with CDDP and VDS
Trial: 8712823
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: UFT daily for 1 year after 2 courses of CDDP
Trial: 8712823
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: Intrapleural administration of OK-432 after lung resection, then UFT and OK-432 once every 2 weeks for 1 year
Trial: 8712823
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (low-grade TP <6.0 g/dl or low response of PPD skin reaction <12mm)
Trial: 1574292
Drug: Intracameral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral injection of sodium hyaluronate (HA) in group B (11 patients)
Trial: 3904559
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg/d for 8 weeks)
Trial: 30782904
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B12 daily supplements (50 μg) to pregnant women
Trial: 17513708
Drug: Basal-bolus insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal-bolus insulin regimen (glargine and glulisine)
Trial: 17513708
Drug: Sliding-scale regular
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sliding-scale regular insulin (SSI)
Trial: 15390055
Drug: 1.125 mg
RxNorm normalized name: Ascorbic Acid/Calcium Pantothenate/Folic Acid/Kava/Lecithin/Niacin/St John's Wort/Thiamine 60 MG-5 MG-0.1 MG-100 MG-15 MG-10 MG-225 MG-1.125 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.125 mg rotigotine (RTG) per day
Trial: 15390055
Drug: 2.25 mg
RxNorm normalized name: serine 2.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.25 mg rotigotine (RTG) per day
Trial: 15390055
Drug: 4.5 mg
RxNorm normalized name: phenol 14.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg rotigotine (RTG) per day
Trial: 15390055
Drug: All rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All rotigotine doses
Trial: 15390055
Drug: 4.5 mg
RxNorm normalized name: phenol 14.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg rotigotine (RTG)
Trial: 9882084
Drug: Dexketoprofen 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen 12.5 mg
Trial: 9882084
Drug: Dexketoprofen 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen 12.5 mg and 25 mg, Ketoprofen 50 mg
Trial: 8018673
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of beta-carotene
Trial: 31172415
Drug: IFN and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN and vaccine for 48 weeks plus IL-2 for 12 weeks (group III)
Trial: 31172415
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III (IFN and vaccine plus IL-2) among patients with baseline HBsAg titers ranging from 100 to 1500 IU/mL
Trial: 31172415
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (IFN) among patients with baseline HBsAg titers ranging from 100 to 1500 IU/mL
Trial: 31172415
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (ETV) among patients with baseline HBsAg titers ranging from 100 to 1500 IU/mL
Trial: 26369563
Drug: Tiotropium HandiHaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium HandiHaler® 18 μg
Trial: 22231764
Drug: Ointment bandage
RxNorm normalized name: New-Skin Liquid Bandage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment bandage (OB)
Trial: 22231764
Drug: IV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV therapy alone
Trial: 15650310
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with grass pollen
Trial: 12404199
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) 0.625 mg
Trial: 12404199
Drug: Estrogen transdermal
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen transdermal patch (ETP) 50 microg
Trial: 10090431
Drug: Timolol maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol maleate ophthalmic gel-forming solution 0.5% (timolol gel) once daily
Trial: 10090431
Drug: Timolol maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol maleate ophthalmic solution 0.5% (timolol solution) twice daily
Trial: 7286051
Drug: Chlorthalidone 75
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 75 mg
Trial: 19790150
Drug: Everolimus with
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus with CNI reduction or discontinuation
Trial: 17846353
Drug: High-dose VIT100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose VIT100 (0.75 mg)
Trial: 17846353
Drug: Low-dose VIT100
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose VIT100 (0.15 mg)
Trial: 15475528
Drug: Intra-arterial aminophylline
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial aminophylline (to block adenosine receptors)